摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

pyrocarboxylic acid di-tert-amyl ester | 87386-81-0

中文名称
——
中文别名
——
英文名称
pyrocarboxylic acid di-tert-amyl ester
英文别名
dipentyl pyrocarbonate;pentoxycarbonyl pentyl carbonate
pyrocarboxylic acid di-tert-amyl ester化学式
CAS
87386-81-0
化学式
C12H22O5
mdl
——
分子量
246.304
InChiKey
LCODWXJBYGHVLO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    17
  • 可旋转键数:
    12
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    61.8
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    pyrocarboxylic acid di-tert-amyl ester羟丙基甲基纤维素邻苯二甲酸酯三乙胺 作用下, 以 氯仿 为溶剂, 反应 60.0h, 以23%的产率得到(1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-yl)-carbamic acid pentyl ester
    参考文献:
    名称:
    Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
    摘要:
    这项发明涉及使用Toll样受体(TLR)7配体及其前药治疗或预防哺乳动物体内的丙型肝炎病毒感染的方法。更具体地,这项发明涉及口服给予一种或多种TLR7配体前药的治疗有效量,用于治疗或预防丙型肝炎病毒感染。将这些TLR7免疫调节配体及其前药口服给哺乳动物可提供治疗有效量并减少不良副作用。
    公开号:
    US20050054590A1
点击查看最新优质反应信息

文献信息

  • MACROCYCLIC PICOLINAMIDES AS FUNGICIDES
    申请人:Dow Agrosciences LLC
    公开号:US20140187588A1
    公开(公告)日:2014-07-03
    The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides.
    本公开涉及式(I)的宏环吡啶酰胺,以及这些化合物作为杀菌剂的使用。
  • beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF
    申请人:Iriyama Yusuke
    公开号:US20120322995A1
    公开(公告)日:2012-12-20
    The invention provides a process for producing a β-dihydrofuran derivative represented by formula (1) or a β-tetrahydrofuran derivative represented by formula (4), characterized in that the process includes causing a dialkyl dicarbonate, a diaralkyl dicarbonate, or a halide to act on a diol compound represented by formula (2) or (3). The invention also provides a process for producing 4′-ethynyl-2′,3′-didehydro-3′-deoxythymidine or an analog thereof, the process including glycosylation and deprotection.
    该发明提供了一种生产由式(1)表示的β-二氢呋喃衍生物或由式(4)表示的β-四氢呋喃衍生物的过程,其特征在于该过程包括使二烷基二碳酸酯、二芳基二碳酸酯或卤化物作用于由式(2)或(3)表示的二醇化合物。该发明还提供了一种生产4'-乙炔基-2',3'-二去氢-3'-脱氧胸苷或其类似物的过程,包括糖基化和去保护。
  • METHOD OF PREPARING COMPLEX-AZO PIGMENT AND COMPLEX-AZO PIGMENT THEREOF
    申请人:OHTA Masafumi
    公开号:US20100010204A1
    公开(公告)日:2010-01-14
    A method of preparing a complex-azo pigment having plural pigment components including at least an azo pigment represented by the following formula (a) A(H)n   (a) Pigments, both limited and unlimited by the process of making.
    制备一种具有多种颜料成分的复杂偶氮颜料的方法,其中至少包括以下公式所代表的偶氮颜料(a)A(H)n。这些颜料在制备过程中既受限制又不受限制。
  • Method for the production of bicyclic aromatic amino acids and intermediate products thereof
    申请人:Wiesner Matthias
    公开号:US20060142568A1
    公开(公告)日:2006-06-29
    Process for the preparation of integrin inhibitors of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 and X have the meanings indicated in Claim 1 , and intermediate compounds.
    制备公式(I)中的整合素抑制剂的过程,其中R1、R2、R3、R4、R5和X的含义如权利要求1所示,并制备中间化合物。
  • ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS
    申请人:Averett Devron R.
    公开号:US20090298863A1
    公开(公告)日:2009-12-03
    This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.
    本发明涉及使用Toll样受体(TLR)7配体及其前药治疗或预防哺乳动物的丙型肝炎病毒感染的方法。更具体地说,本发明涉及口服治疗丙型肝炎病毒感染的一种或多种TLR7配体前药的治疗剂量的方法。将这些TLR7免疫调节配体及其前药口服给哺乳动物,可提供治疗有效量和减少不良副作用。
查看更多